ORIC Pharmaceuticals, Inc. (ORIC)

USD 7.68

(-6.91%)

Market Cap (In USD)

541.95 Million

Revenue (In USD)

-

Net Income (In USD)

-100.69 Million

Avg. Volume

598.5 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.33-16.65
PE
-
EPS
-
Beta Value
1.122
ISIN
US68622P1093
CUSIP
68622P109
CIK
1796280
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jacob M. Chacko M.B.A., M.D.
Employee Count
-
Website
https://www.oricpharma.com
Ipo Date
2020-04-24
Details
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.